VENUS REMEDIES Fact Sheet, VENUS REMEDIES Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Fact Sheet    (VSRM)


RELEASED: Richa Agarwal's No. 1 Stock Pick for 2021


Here is the latest financial fact sheet of VENUS REMEDIES. For more details, see the VENUS REMEDIES quarterly results and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

VENUS REMEDIES Price History

Price Rs 133.7
Mkt Cap Rs m 1,530
Vol '000 1.7
P/E X -6.3
P/CF X 48.7
EPS (TTM) Rs -21.1
% ch % 5.0
No. of shares m 11.44
% ch week % 28.4
% ch 1-mth % 38.7
% ch 12-mth % 476.3
52 week H/L Rs 133.7/19.5
(As on Sep 18, 2020 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

VENUS REMEDIES Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
VENUS REMEDIES EQUITY SHARE DATA
High Rs358330218143126 
Low Rs140103826561 
Sales per share (Unadj.) Rs473.4405.6365.6324.2301.8 
Earnings per share (Unadj.) Rs56.24.51.5-13.8-24.9 
Diluted earnings per shareRs56.24.51.5-14.9-26.8 
Cash flow per share (Unadj.) Rs91.444.737.918.82.5 
Dividends per share (Unadj.) Rs00000 
Adj. dividends per shareRs0.000.000.000.000.00 
Dividend yield (eoy) %00000 
Book value per share (Unadj.) Rs403.5399.2382.5315.0293.3 
Adj. book value per shareRs403.5399.2382.5339.7316.4 
Shares outstanding (eoy) m11.4411.4411.4412.3412.34 
Bonus/Rights/Conversions  WC---- 
Price / Sales ratio x0.50.50.40.30.3 
Avg P/E ratio x4.447.9101.0-7.5-3.8 
P/CF ratio (eoy) x2.74.84.05.536.7 
Price / Book Value ratio x0.60.50.40.30.3 
Dividend payout %00000 
Avg Mkt Cap Rs m2,8492,4711,7171,2821,154 
No. of employees `000NANA1.00.90.9 
Total wages/salary Rs m305324250343393 
Avg. sales/employee Rs ThNMNM4,100.74,430.14,026.1 
Avg. wages/employee Rs ThNMNM245.3379.5425.0 
Avg. net profit/employee Rs ThNMNM16.7-189.1-331.8 
VENUS REMEDIES INCOME DATA
Net Sales Rs m5,4164,6404,1834,0003,724 
Other income Rs m57202323 
Total revenues Rs m5,4204,6474,2034,0233,747 
Gross profit Rs m1,382892812507395 
Depreciation Rs m402460417403338 
Interest Rs m294412380344354 
Profit before tax Rs m6912735-216-275 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m48-2518-4632 
Profit after tax Rs m6435217-171-307 
Gross profit margin %25.519.219.412.710.6 
Effective tax rate %6.9-94.851.621.1-11.5 
Net profit margin %11.91.10.4-4.3-8.2 
VENUS REMEDIES BALANCE SHEET DATA
Current assets Rs m2,7212,6752,7592,5942,638 
Current liabilities Rs m2,1101,9651,9201,9682,305 
Net working cap to sales %11.315.320.115.68.9 
Current ratio x1.31.41.41.31.1 
Inventory Days Days96112125128135 
Debtors Days Days4450544346 
Net fixed assets Rs m5,0735,2195,2885,0564,871 
Share capital Rs m114114114123123 
"Free" reserves Rs m4,4504,4453,8833,7633,496 
Net worth Rs m4,6164,5674,3763,8873,619 
Long term debt Rs m1,4001,6861,9111,6181,374 
Total assets Rs m8,3448,4118,0477,6507,509 
Interest coverage x3.31.11.10.40.2 
Debt to equity ratio x0.30.40.40.40.4 
Sales to assets ratio x0.60.60.50.50.5 
Return on assets %11.25.54.92.30.6 
Return on equity %13.91.10.4-4.4-8.5 
Return on capital %16.47.06.62.31.6 
Exports to sales %00000 
Imports to sales %17.017.720.518.413.9 
Exports (fob) Rs m00000 
Imports (cif) Rs m921821858736517 
Fx inflow Rs m00000 
Fx outflow Rs m921822858736517 
Net fx Rs m-921-822-858-736-517 
VENUS REMEDIES CASH FLOW
From Operations Rs m 527 678 469 589 514 
From Investments Rs m -947 -672 29 -183 -123 
From Financial Activity Rs m 401 -14 -464 -441 -387 
Net Cashflow Rs m -20 -8 35 -35 4 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 32.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.2%
FIIs 0.6%
ADR/GDR 0.0%
Free float 66.4%
Shareholders 20,121
Pledged promoter(s) holding 36.4%
 

Company Information

REGD OFF SCO 857, 2nd Floor, Cabin No. 10, NAC Manimajra, Chandigarh-160 101
E-MAIL investorgrievance@venusremedies.com WEB www.venusremedies.com
TELEPHONE (0172) 393 3094 FAX (0172) 256 5566
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, A-31, Naraina Indl. Area, Phase 1, New Delhi-28
AUDITOR J. K. Jain & Assoc.
CHM: Pawan Chaudhary (MD) COMP SEC: Neha Kodan YEAR OF INC: 1989 BSE CODE: 526953 FV (Rs): 10 DIV YIELD (%): -

Read: VENUS REMEDIES 2017-18 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   J.B.CHEMICALS  GSK PHARMA  CIPLA  ORCHID PHARMA LTD  GLENMARK PHARMA  

Compare VENUS REMEDIES With:   J.B.CHEMICALS  GSK PHARMA  CIPLA  ORCHID PHARMA LTD  GLENMARK PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  




Today's Market

Sensex Ends 134 Points Lower; Finance and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure during closing hours today and ended marginally lower.

Views on news

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - MYLAN COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS